The Past, Present, and Future (liquid Biopsy) of Serum Tumor Markers in Lung Cancer: A Primer for the Radiologist

Abstract Lung cancer continues to be a major cause of death throughout the world. The ability to both accurately diagnose lung cancer in its early stages and monitor response to treatment is essential to reducing the morbidity and mortality associated with the disease. Serum tumor markers have been identified as potential biomarkers that may aid in lung cancer diagnosis and surveillance. These markers, when combined with cross-sectional imaging, may result in more robust screening and surveillance protocols. The future role of serum tumor markers in lung cancer includes the advancement of “liquid biopsies,” in which peripheral blood samples are analyzed for tumor components without the need for a tissue biopsy.